<?xml version="1.0" encoding="UTF-8"?>
<p id="para0027">If conditioning has proceeded to a point at which the risk of myelosuppression or myeloablation is low, then subsequent doses may be withheld. If conditioning duration/intensity has passed that point, then conditioning should be completed and the HCT product infused. If sufficient myeloablative conditioning has been delivered to a recipient and SARS-CoV-2 is confirmed, the transplantation process should continue owing to anticipated bone marrow aplasia. The COVID-19 infection should be managed symptomatically or on a clinical trial with a cautious evaluation of drug-drug interactions.</p>
